---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-009782"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:22:57.822007+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lixte reports new pre-clinical data on LB-100 activation and potential biomarker for patient response

## Summary
- Enzyme discovered that converts LB-100 to active metabolite endothall, published in BioXriv and Int'l J. Pharmaceutics.
- Findings open potential biomarker strategy to identify patients most likely to respond to LB-100.
- LB-100 also spontaneously converts via slow hydrolysis; enzymatic conversion inside cell expedites activation.
- Clinical trials for LB-100 in ovarian and colorectal cancer continue; CEO says data will help optimize patient selection.

## SEC filing metadata
- accession: 0001493152-25-009782
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315225009782/0001493152-25-009782-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315225009782/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-009782
- JSON: https://secwatch.observer/filing/0001493152-25-009782.json
- Plain text: https://secwatch.observer/filing/0001493152-25-009782.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.